预约演示
更新于：2025-05-31
Amlodipine Besylate/Benazepril Hydrochloride
氨氯地平贝那普利
更新于：2025-05-31
概要
基本信息
药物类型 小分子化药 |
别名 Amlodipine Besylate and Benazepril Hydrochloride、Amlodipine/benazepril、Lotrel + [1] |
作用方式 抑制剂、阻滞剂 |
作用机制 ACE抑制剂(血管紧张素转化酶抑制剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-03-03), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29ClN2O5 |
InChIKeyVPSRQEHTHIMDQM-FKLPMGAJSA-N |
CAS号86541-74-4 |
查看全部结构式(2)
关联
46
项与 氨氯地平贝那普利 相关的临床试验CTR20250418
氨氯地平贝那普利胶囊（5 mg/10 mg）在健康受试者中餐后条件下的生物等效性试验
CTR20250421
氨氯地平贝那普利胶囊（5 mg/10 mg）在健康受试者中空腹条件下的生物等效性试验
CTR20243734
左氨氯地平贝那普利胶囊在中国成年健康受试者中的生物等效性研究
100 项与 氨氯地平贝那普利 相关的临床结果
登录后查看更多信息
100 项与 氨氯地平贝那普利 相关的转化医学
登录后查看更多信息
100 项与 氨氯地平贝那普利 相关的专利（医药）
登录后查看更多信息
12
项与 氨氯地平贝那普利 相关的文献（医药）2022-09-01Annals of palliative medicine
Hypertension as a rare adverse effect caused by infliximab in the treatment of Crohn’s disease: a case report
作者: Mo, Jiahao ; Zhao, Xiying ; Tang, Jian ; Zhang, Beiping
BACKGROUND:
Infliximab is an effective drug for the treatment of Crohn's disease. As a rare and unique adverse effect of infliximab, hypertension should be paid enough attention in clinical work. At present, there is no relevant case report. We report a case of a 38-year-old man with Crohn's disease who had no history of hypertension and developed hypertension symptoms during infliximab treatment.
CASE DESCRIPTION:
The patient was treated with 5 mg/kg infliximab on August 27, 2020. From August 27, 2020 to October 20, 2020, the patient underwent 3 treatment sessions. After each injection of infliximab, the patient's blood pressure became elevated, accompanied by dizziness and symmetrical numbness of both lower limbs. Amlodipine benazepril tablets were given orally to control blood pressure. Under close monitoring, 5 mg/kg infliximab was used again. After 10 min of infusion, blood pressure rose to 160/118 mmHg. Infusion was discontinued immediately, after which blood pressure decreased to normal. Adrenal computed tomography did not indicate adrenal hyperplasia or space occupying lesions, and the detection of hypertension related indicators in standing and supine position was abnormal. Since follow up, the patient has stopped using infliximab and has had no hypertension-related symptoms, even without antihypertensives. Measured blood pressure was within the normal range.
CONCLUSIONS:
Hypertension, as one of the rare adverse reactions of infliximab in the treatment of Crohn's disease, should be paid enough attention.
2013-07-01American journal of hypertension3区 · 医学
Dynamic View on Affordability of Fixed-Dose Combination Antihypertensive Drug Therapy
3区 · 医学
Article
作者: Junling Wang ; Jun Tang ; Song Hee Hong
BACKGROUND:
The use of fixed-dose combinations (FDCs) has been increasing since the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended using ≥2 drugs as the first-line drug therapy for patients with stage 2 hypertension. FDCs simplify the drug therapy regimen and reportedly lower the drug therapy cost compared with the free combination (FC) of 2 single-agent drugs. This study hypothesized that the affordability of FDCs over FCs would change over time depending on the availability of generic single-agent drugs.
METHODS:
This study used the 2009 Medical Expenditure Panel Survey. Antihypertensive drugs were identified based on the Food and Drug Administration national drug directory. Based on the 2 databases, regression models were run to predict average monthly drug cost as well as out-of-pocket cost for each prescription along with their 95% confidence intervals (CIs).
RESULTS:
Overall, FDCs (n = 26) had average monthly drug costs similar to respective FCs when FCs were not generically available. However, when FCs were generically available, FDCs (n = 11) had average drugs costs much higher than their respective FCs. For example, Lotrel as an FDC had an average monthly drug cost of $115.97 (95% CI = $96.59-$135.36), whereas its counterpart FC had an average monthly drug cost of $21.00 (95% CI = $18.23-$23.79).
CONCLUSIONS:
The cost advantage of FDCs over FCs was reversed when FCs were generically available. The finding of this study informs patients, health-care providers, and drug plans of the importance of making dynamic decisions on preferred drug therapy options depending on the availability of generic drugs.
2012-08-01Clinical therapeutics4区 · 医学
Comparison of the Efficacy and Safety Profiles of Two Fixed-Dose Combinations of Antihypertensive Agents, Amlodipine/Benazepril Versus Valsartan/Hydrochlorothiazide, in Patients With Type 2 Diabetes Mellitus and Hypertension: A 16-Week, Multicenter, Randomized, Double-Blind, Noninferiority Study
4区 · 医学
Article
作者: I-Te Lee ; Chih-Yuan Wang ; Jung-Fu Chen ; Wen-Jane Lee ; Wayne Huey-Herng Sheu ; Yi-Jen Hung
BACKGROUND:
Hypertension is a prevalent condition that is closely associated with chronic complications in patients with diabetes. Fixed-dose combination therapy is currently recommended for the treatment of hypertension due to the advantage of reducing the pill burden. However, the effects of combination therapy may be diverse because of the different components.
OBJECTIVES:
We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria.
METHODS:
This randomized, double-blind, parallel comparison, noninferiority clinical trial included patients with type 2 diabetes mellitus and hypertension and microalbuminuria detected within the past year. After a 2-week, placebo run-in period, patients were assigned to treatment with amlodipine/benazepril or valsartan/hydrochlorothiazide for 16 weeks. The primary end point was mean change in diastolic blood pressure. The prespecified boundary for noninferiority was 3.5 mm Hg of the mean change in diastolic blood pressure between treatments (amlodipine/benazepril minus valsartan/hydrochlorothiazide). If the upper limit of the 95% CI fell within 3.5 mm Hg, amlodipine/benazepril would be considered noninferior to valsartan/hydrochlorothiazide.
RESULTS:
Of the 226 patients assessed for eligibility, 169 satisfied the inclusion/exclusion criteria and were assigned to a treatment group; 83 patients (54.2% male, mean age of 60.5 [10.0] years) in the amlodipine/benazepril group and 84 patients (64.3% male, mean age of 59.0 [10.6] years) in the valsartan/hydrochlorothiazide group received at least 1 dose of study medication and were included in the intention-to-treat population. In the per-protocol population, amlodipine/benazepril (n = 74) was noninferior to valsartan/hydrochlorothiazide (n = 78) with regard to the mean change in diastolic blood pressure (difference, -0.9 mm Hg; 95% CI, -3.5 to 1.6). The mean change in systolic blood pressure was not significantly different (2.4 mm Hg; 95% CI, -1.2 to 6.0) between study groups (P = 0.195) in the per-protocol population. However, data from the intention-to-treat population suggest that patients in the amlodipine/benazepril group may have better metabolic outcomes than those in the valsartan/hydrochlorothiazide group; specifically, a preservation of the estimated glomerular filtration rate (5.7 mL/min/1.73 m(2) [95% CI, 1.9 to 9.6]; P = 0.004) and improvements in glycosylated hemoglobin (-0.5% [95% CI, -0.7 to -0.2]; P < 0.001), fasting triglycerides (-0.4 mmol/L [95% CI, -0.7 to -0.2]; P = 0.002), HDL-C (0.07 mmol/L [95% CI, 0.01 to 0.12]; P = 0.022), and uric acid (-57.5 μmol/L [95% CI, -74.8 to -40.3]; P < 0.001). There were no significant differences in adverse effects between groups, with the exception of more respiratory disorders in the amlodipine/benazepril group than in the valsartan/hydrochlorothiazide group (17 vs 5; P = 0 .006).
CONCLUSIONS:
The study results suggest that amlodipine/benazepril is noninferior to valsartan/hydrochlorothiazide with regard to blood pressure reduction and that this combination exerts beneficial effects on renal function, glucose control, HDL-C, and triglyceride levels compared with valsartan/hydrochlorothiazide. However, respiratory adverse events (particularly coughing) were more frequently reported in the amlodipine/benazepril group. ClinicalTrials.gov identifier: NCT01375322.
100 项与 氨氯地平贝那普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 1995-03-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 美国 | 2004-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 226 | 襯鏇選築糧製淵願膚構(鏇構簾願鏇壓構獵膚壓) = more frequently reported in the amlodipine/benazepril group than in the valsartan/hydrochlorothiazide group 遞觸範顧壓壓醖憲網鑰 (構網鑰積願遞憲網簾衊 ) | - | 2012-08-01 | |||
临床3期 | 11,506 | (Benazepril/Amlodipine) | 繭壓糧衊構餘鏇範簾構 = 襯繭觸廠鏇夢憲遞遞鹹 醖襯鏇衊鬱築膚廠範構 (範淵鹹築積簾淵顧鬱構, 壓顧夢醖繭遞衊獵構築 ~ 蓋築窪齋衊鏇餘築鬱餘) 更多 | - | 2011-05-17 | ||
(Benazepril/Hydrochlorothiazide) | 繭壓糧衊構餘鏇範簾構 = 憲鏇衊製積顧艱衊築構 醖襯鏇衊鬱築膚廠範構 (範淵鹹築積簾淵顧鬱構, 簾餘衊積廠醖鹽顧鹹淵 ~ 網顧壓遞鬱製鏇鑰餘憲) 更多 | ||||||
临床1期 | - | 68 | (Amlodipine Benazepril) | 網觸鬱齋淵醖獵窪鑰構(鑰齋獵簾積壓餘製鏇構) = 憲膚襯窪窪製繭鏇鏇顧 衊衊壓顧淵襯襯鑰蓋顧 (鑰構願醖鑰廠憲遞艱選, 1079.24) 更多 | - | 2009-08-18 | |
(Lotrel®) | 網觸鬱齋淵醖獵窪鑰構(鑰齋獵簾積壓餘製鏇構) = 蓋鹽鹹築簾鹽衊廠齋網 衊衊壓顧淵襯襯鑰蓋顧 (鑰構願醖鑰廠憲遞艱選, 1183.43) 更多 | ||||||
临床1期 | - | 48 | (Amlodipine Benazepril) | 窪蓋選獵艱鹽淵觸衊繭(窪簾窪憲願廠憲蓋壓築) = 築獵壓構製夢衊蓋壓糧 鑰衊襯夢淵艱壓遞艱鑰 (範範齋構壓構憲廠願顧, 1917.69) 更多 | - | 2009-08-18 | |
(Lotrel®) | 窪蓋選獵艱鹽淵觸衊繭(窪簾窪憲願廠憲蓋壓築) = 範醖膚艱獵繭衊衊鹹蓋 鑰衊襯夢淵艱壓遞艱鑰 (範範齋構壓構憲廠願顧, 1697.24) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用